STOCK TITAN

Rubric Capital discloses 2.94% Trevi Therapeutics (TRVI) stake

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Rubric Capital Management LP and David Rosen report beneficial ownership of 3,766,749 shares of Trevi Therapeutics, Inc. common stock, equal to 2.94% of the outstanding shares based on 128,230,134 shares as of October 31, 2025. They share voting and dispositive power over all reported shares and indicate that the position is held in the ordinary course of business. They state the holdings were not acquired and are not held to change or influence control of Trevi Therapeutics.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Rubric Capital Management LP
Signature:/s/ Michael Nachmani
Name/Title:Michael Nachmani / Chief Operating Officer
Date:02/13/2026
David Rosen
Signature:/s/ David Rosen
Name/Title:David Rosen / Individually
Date:02/13/2026

FAQ

Who is reporting ownership of Trevi Therapeutics (TRVI) shares in this Schedule 13G/A?

The filing shows Rubric Capital Management LP and David Rosen as reporting persons. Rubric Capital advises certain investment funds holding Trevi Therapeutics common stock, and Rosen is Managing Member of Rubric Capital Management GP LLC, Rubric Capital’s general partner.

How many Trevi Therapeutics (TRVI) shares do Rubric Capital and David Rosen beneficially own?

They report beneficial ownership of 3,766,749 Trevi Therapeutics common shares. This amount is attributed to investment funds and accounts advised by Rubric Capital, over which they share both voting power and dispositive power according to the Schedule 13G/A.

What percentage of Trevi Therapeutics (TRVI) does Rubric Capital’s position represent?

The filing states a beneficial ownership of 2.94% of Trevi Therapeutics’ common stock. This percentage is calculated using 128,230,134 shares outstanding as of October 31, 2025, as reported in Trevi’s Form 10-Q for the quarter ended September 30, 2025.

Do Rubric Capital and David Rosen have sole or shared voting power over Trevi Therapeutics (TRVI) shares?

They report 0 shares with sole voting power and 3,766,749 shares with shared voting power. They also report no sole dispositive power and shared dispositive power over the same 3,766,749 Trevi Therapeutics common shares.

Are Rubric Capital’s Trevi Therapeutics (TRVI) shares held to influence control of the company?

The certification states the securities were acquired and are held in the ordinary course of business. It further states they were not acquired and are not held to change or influence control of Trevi Therapeutics or in connection with any such control transaction.

What type of reporting persons are listed for the Trevi Therapeutics (TRVI) Schedule 13G/A?

Rubric Capital Management LP is classified as an investment adviser (IA), organized in Delaware. David Rosen is classified as a HC (parent holding company or control person) and is a citizen of the United States, according to the ownership cover pages.
Trevi Therapeutics

NASDAQ:TRVI

TRVI Rankings

TRVI Latest News

TRVI Latest SEC Filings

TRVI Stock Data

1.40B
113.69M
0.72%
92.78%
9.6%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW HAVEN